Biomarkers

PreclinicalBiologic

CCiusss de L'Est de l'Île de Montréal

Biomarkers is one of 10 biologic programs targeting Opioid. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OpioidTerminated

OpioidPreclinical

Terminated

Competition

Competitive Landscape

12 competitors in Opioid

#DrugCompanyPhaseTrials

Oxycontin

PProtega

Phase 3

4 2

Revia

Teva

Phase 2

6 3

Epidiolex

Jazz Pharmaceuticals

Phase 2

1 4

Suboxone

Merck & Co.

Phase 3

1 5

Narcan

SScienture

Phase 1

7 6

DOVATO

GSK

Phase 3

1 7

Alfenta

Jazz Pharmaceuticals

Preclinical

1 8

Barhemsys

Tibotec Pharmaceuticals, Ireland

Preclinical

1 9

Imodium

KKenvue Brands

Phase 1

1 10

Biomarkers

CCiusss de L'Est de l'Île de Montréal

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Opioid1 trial

Correlation Between NOL Index After Stimulus and Post-operative Opioid, Pain, Pre-operative Phenotype

Terminated·CCiusss de L'Est de l'Île de Montréal·N/A·NCT03422783·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Biomarkers. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biomarkers compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biomarkers. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ciusss de L'Est de l'Île de Montréal company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: CCiusss de L'Est de l'Île de Montréal

Biomarkers

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Opioid1 trial

References

Drug Info

Quick Facts

Related News